Primary Immune Thrombocytopenia (ITP) Clinical Trial
Official title:
Study of Immune Thrombocytopenia Pathogenesis: a Multicenter, Open and Controlled Study.
Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a low platelet count
responsible for bleedings. The disease is mostly mediated by antiplatelet antibodies produced
by specific B cells. However, T cells are also involved but their role is not completely
understood.
The aim of this study is to determine the implication of T cells in the pathogenesis of ITP,
notably regulatory T cells (Treg, CD4+CD25highFoxp3+), cytotoxic T cells (CD3+CD8+) and T
follicular helper cells (TFH, CD3+CD4+CXCR5+PD-1+ICOS+), in blood and in the spleen of
primary ITP patients, compared to healthy controls.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04812483 -
Immunomodulation With Eltrombopag in ITP
|
Phase 2 | |
| Active, not recruiting |
NCT05029635 -
Phase III Study on HMPL-523 for Treatment of ITP
|
Phase 3 | |
| Recruiting |
NCT05338190 -
Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia
|
Phase 3 | |
| Recruiting |
NCT05653349 -
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
|
Phase 3 | |
| Withdrawn |
NCT04274452 -
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP)
|
Phase 3 | |
| Recruiting |
NCT05718856 -
TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
|
Phase 4 | |
| Recruiting |
NCT05885555 -
A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
|
Phase 2 | |
| Recruiting |
NCT04518475 -
Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults
|
Phase 4 |